ストックスクリーナーアプリを入手
1.84
1.10%
0.02
プレマーケット:
1.86
0.02
+1.09%
Allogene Therapeutics Inc (ALLO) 最新ニュース
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - MSN
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL
Barclays PLC Buys 172,745 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
JPMorgan Chase & Co. Sells 37,348 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
Zacks Research Issues Pessimistic Estimate for ALLO Earnings - Defense World
What is Zacks Research's Forecast for ALLO Q2 Earnings? - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $9.73 Consensus Price Target from Brokerages - MarketBeat
Head-To-Head Review: Allogene Therapeutics (NASDAQ:ALLO) versus Precision BioSciences (NASDAQ:DTIL) - Defense World
Geode Capital Management LLC Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Holdings Boosted by Geode Capital Management LLC - Defense World
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Benzinga
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
State Street Corp Has $19.64 Million Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - MarketBeat
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - MSN
Allogene stock hits 52-week low at $1.98 amid market challenges - Investing.com Canada
Allogene stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa
Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal phase - Investing.com
Allogene Therapeutics (ALLO) Stock Drops Amidst Biotech Sector Decline - GuruFocus.com
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - The Manila Times
Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - GlobeNewswire
Allogene Therapeutics, Inc. Acknowledges the Passing of Founding Board Member David Bonderman - Marketscreener.com
Insider Sell: Deborah Messemer Sells 9,136 Shares of Allogene Th - GuruFocus.com
Allogene Therapeutics: Showing Promise Despite Some Shaky Safety (NASDAQ:ALLO) - Seeking Alpha
Zacks Investment Management Purchases New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (ALLO) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Fmr LLC Reduces Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Decrease in Short Interest - MarketBeat
Allogene Therapeutics Loses 23% Year To Date: How To Play The Stock? - Barchart
Vestal Point Capital LP Trims Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene’s ALLO-329 shows efficacy at killing CD19- and CD70-expressing cells - BioWorld Online
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ALLO (Allogene Therapeutics) Investments And Advances : $111.82 Mil (As of Sep. 2024) - GuruFocus.com
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth? - Simply Wall St
Allogene stock touches 52-week low at $2 amid market challenges - Investing.com India
4.81%
大文字化:
|
ボリューム (24 時間):